Gary Glick

Gary D.
Glick was the founder of Lycera Corp.
(founded 2006), serving as Chief Science Officer & Director from 2010 to 2011.
Dr. Glick was the founder of Scorpion Therapeutics, Inc. (founded 2020), serving as Director from 2020 to 2021.
Dr. Glick is the founder of IFM Therapeutics LLC (founded 2015), serving as Executive Chairman since 2019.
Dr. Glick is the founder of First Wave Bio, Inc. (founded 2015), serving as Chief Executive Officer & Director since 2015.
Dr. Glick is the founder of Odyssey Therapeutics, Inc. (founded 2021), serving as President, Chief Executive Officer & Director since 2021.
Current jobs include Chief Executive Officer at Charm Therapeutics Ltd. starting 2022, Director at IFM Cinque, Inc., IFM Continua, Inc., and IFM Quattro, Inc., President & Director at IFM Due, Inc., and Counselor-Biological Chemistry Division at American Chemical Society since 2013.
Former jobs include Director-Advisory Board at National Institutes of Health, President & Director at Novartis Inflammasome Research, Inc., Faculty Member at the University of Michigan in 2013, Advisor at Delin Ventures Ltd., and Senior Advisor at Abingworth Management, Inc. Education includes a doctorate degree conferred in 1988 from The Trustees of Columbia University in The City of New York.